USF Health is providing COVID-19 vaccinations by invitation and appointment only to patients and employees who meet eligibility criteria defined by Florida Executive Order as supply of vaccine permits. Learn More.
Christian Bréchot, MD, PhD joined the USF Health Morsani College of Medicine part time as Senior Associate Dean for Research in Global Affairs, Associate Vice President for International Partnerships and Innovation, and Professor in the Division of Infectious Disease, Department of Internal Medicine. He is also executive director of the Tampa-based Romark Laboratories Institute for Medical Research. Since 2017, Dr. Bréchot has served as President of the Global Virus Network, a network of 48 research centers worldwide, headquartered in Baltimore.
Before serving as president of the Pasteur Institute from 2013 to 2017, Dr. Bréchot was vice president of medical and scientific affairs at Institut-Merieux, a company that develops new approaches to fight infectious diseases and cancers. He also served as the General Director of Inserm, the French national agency for biomedical research from 2002 to 2007. As professor of hepatology and cell biology at Necker School of Medicine, Paris Descartes University, he led the clinical department of liver diseases at Necker-Enfants Maldes Hospital from 1997 to 2001.
Authoring more than 400 articles in medical and scientific journals, Dr. Bréchot was ranked by the Institute for Scientific Information as the 4th most cited author on the topic of hepatitis C. He has been recognized as an inventor on 18 patents, and helped create three biotechnology companies: Rarecells, ALFACT Innovation, and The Healthy Aging Company.
Dr. Bréchot’s research activities have focused on viral hepatitis: hepatitis B (HBV) and C (HCV), particularly with regard to their role in liver cancer (Hepatocellular carcinoma: HCC) and to the molecular mechanisms that drive liver regeneration and cancer (in particular, cell cycle deregulation and the impact of oxydative stress). Additionally, Dr. Bréchot’s research interests also include microbiomes, particularly in the area of microbiomes and viral infections. In this respect, he is a co-founder of the Microbiome, Immunology and Infection Control (MIIM) in the USF Pandemic Response Research Network (PRRN). This research hub focuses on enabling and connecting an interdisciplinary network of scientists at USF and globally. The hub's goals are to develop precision therapies and interventions that target the human microbiome to maintain and restore human health against COVID-19 and future such pandemics. Dr. Bréchot is also head of the USF Initiative on Microbiomes. He has been the member of numerous scientific committees and societies and has received prestigious awards.
Whiteson KL, Bohannan BJM, David LA, Hynson NA, McFall-Ngai M, et al. The
emergence of microbiome centres. Nat Microbiol. 2020;5(1):2-3. Epub 2019/12/21.
doi: 10.1038/s41564-019-0644-x. PubMed PMID: 31857734.
Ascierto PA, Morse GD, Buonaguro L, Puzanov I, Tornesello ML, et al. Covid-19:
Time for a paradigm change. Rev Med Virol. 2020;30(5):e2134. Epub 2020/07/04.
doi: 10.1002/rmv.2134. PubMed PMID: 32618072; PubMed Central PMCID:
Brechot C. [The
pandemic caused by SARS-CoV-2: more than a serious health crisis, a change of
time and lessons to be learned urgently]. Med Sci (Paris). 2020;36(12):1107-8.
Epub 2020/11/18. doi: 10.1051/medsci/2020245. PubMed PMID: 33200980.
Brechot C. A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic
Hepatitis B. Hepatol Commun. 2019;3(6):744-7. Epub 2019/06/07. doi:
10.1002/hep4.1339. PubMed PMID: 31168509; PubMed Central PMCID: PMCPMC6546020.
Revill PA, Penicaud
C, Brechot C, Zoulim F. Meeting the Challenge of Eliminating Chronic Hepatitis
B Infection. Genes (Basel). 2019;10(4). Epub 2019/04/04. doi:
10.3390/genes10040260. PubMed PMID: 30939846; PubMed Central PMCID:
Brechot C, Bryant J,
Endtz H, Garry RF, Griffin DE, Lewin SR, et al. 2018 international meeting of
the Global Virus Network. Antiviral Res. 2019;163:140-8. Epub 2019/01/29. doi:
10.1016/j.antiviral.2019.01.013. PubMed PMID: 30690044; PubMed Central PMCID:
Akkina R, Garry R,
Brechot C, Ellerbrok H, Hasegawa H, Menendez-Arias L, et al. 2019 meeting of
the global virus network. Antiviral Res. 2019;172:104645. Epub 2019/11/08. doi:
10.1016/j.antiviral.2019.104645. PubMed PMID: 31697957; PubMed Central PMCID:
Lazarus JV, Block T,
Brechot C, Kramvis A, Miller V, Ninburg M, et al. The hepatitis B epidemic and
the urgent need for cure preparedness. Nat Rev Gastroenterol Hepatol.
2018;15(9):517-8. Epub 2018/07/28. doi: 10.1038/s41575-018-0041-6. PubMed PMID:
Darnaud M, Dos
Santos A, Gonzalez P, Augui S, Lacoste C, Desterke C, et al. Enteric Delivery
of Regenerating Family Member 3 alpha Alters the Intestinal Microbiota and
Controls Inflammation in Mice With Colitis. Gastroenterology.
2018;154(4):1009-23 e14. Epub 2017/11/15. doi: 10.1053/j.gastro.2017.11.003.
PubMed PMID: 29133078.
Perkins MD, Dye C,
Balasegaram M, Brechot C, Mombouli JV, Rottingen JA, et al. Diagnostic
preparedness for infectious disease outbreaks. Lancet. 2017;390(10108):2211-4.
Epub 2017/06/05. doi: 10.1016/S0140-6736(17)31224-2. PubMed PMID: 28577861.